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OBJECTIVE—The redox enzyme p66Shc produces hydrogen
peroxide and triggers proapoptotic signals. Genetic deletion of
p66Shc prolongs life span and protects against oxidative stress.
In the present study, we evaluated the role of p66Shc in an animal
model of diabetic wound healing.
RESEARCH DESIGN AND METHODS—Skin wounds were
created in wild-type (WT) and p66Shc
/ control and streptozo-
tocin-induced diabetic mice with or without hind limb ischemia.
Wounds were assessed for collagen content, thickness and
vascularity of granulation tissue, apoptosis, reepithelialization,
and expression of c-myc and -catenin. Response to hind limb
ischemia was also evaluated.
RESULTS—Diabetes delayed wound healing in WT mice with
reduced granulation tissue thickness and vascularity, increased
apoptosis, epithelial expression of c-myc, and nuclear localiza-
tion of -catenin. These nonhealing features were worsened by
hind limb ischemia. Diabetes induced p66Shc expression and
activation; wound healing was signiﬁcantly faster in p66Shc
/
than in WT diabetic mice, with or without hind limb ischemia, at
1 and 3 months of diabetes duration and in both SV129 and
C57BL/6 genetic backgrounds. Deletion of p66Shc reversed non-
healing features, with increased collagen content and granulation
tissue thickness, and reduced apoptosis and expression of c-myc
and -catenin. p66Shc deletion improved response to hind limb
ischemia in diabetic mice in terms of tissue damage, capillary
density, and perfusion. Migration of p66Shc
/ dermal ﬁbro-
blasts in vitro was signiﬁcantly faster than WT ﬁbroblasts under
both high glucose and hypoxia.
CONCLUSIONS—p66Shc is involved in the delayed wound-
healing process in the setting of diabetes and ischemia. Thus,
p66Shc may represent a potential therapeutic target against this
disabling diabetes complication. Diabetes 59:2306–2314, 2010
I
mpaired cutaneous wound healing is a major source
of morbidity and mortality in the diabetic population
(1,2). It is estimated that foot ulcers affect about 15%
of diabetic patients with an annual amputation rate
of about 1% (3). Importantly, mortality after a major
amputation is very high (4). Chronic nonhealing ulcers
also lead to disability and have a profound negative impact
on patients’ quality of life (5). The pathophysiology of
chronic diabetic ulcers is complex and still incompletely
understood, the most important predisposing factors be-
ing diabetic neuropathy and vasculopathy. Both micro-
and macroangiopathy strongly contribute to development
and delayed healing of diabetic wounds, through an im-
paired tissue feeding and response to ischemia. Wound
healing is a complex physiological process that integrates
the cooperation of multiple cell types, including the epi-
thelium, endothelium, and ﬁbroblasts (6). The biochemical
basis of delayed wound healing in diabetes resembles the
pathogenesis of other chronic complications, and includes
stimulation of the polyol and glucosamine pathways, over-
activity of protein kinase C and mitogen-activated protein
kinase, and formation of advanced glycation end products.
Oxidative stress is recognized as the common precursor
mechanism of all these biochemical alterations (7). In
diabetes, excessive reactive oxygen species (ROS) are
produced either in the cytoplasm through the NADPH
oxidase (8) or in mitochondria, through respiratory chain
overﬂow. One source of mitochondrial ROS is the 66-kDa
isoform of the mammal ShcA gene, p66Shc (9). Once
believed to act as a docking adaptor protein for mitogenic
signals, p66Shc has been characterized as a redox enzyme
that, upon phosphorylation on serine 36, translocates into
the mitochondrial intermembrane space and catalyzes the
production of hydrogen peroxide (H2O2). This eventually
causes mitochondrial permeability transition and leads the
way to apoptotic cell death.
We have previously shown that the expression of
p66Shc is increased in diabetic patients in relation to
glucose control and markers of oxidative stress (10). This
observation formed the basis to explore the role of p66Shc
in diabetes complications. Genetic deletion of p66Shc in
mice confers resistance to oxidative damage and prolongs
life span (11). Interestingly, some studies show that
p66Shc
/ mice are protected from the development of
certain diabetes complications, such as nephropathy, en-
dothelial dysfunction, and cardiomyopathy (12–14).
In the present study, we tested the hypothesis that
p66Shc is involved in the delayed wound healing induced
by diabetes and ischemia, and that p66Shc knockout
improves features of wound healing in these settings. We
show that deletion of p66Shc reverses many features of
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paired development and vascularization of the granulation
tissue, response to ischemia, and reepithelialization.
RESEARCH DESIGN AND METHODS
An expanded description of materials and methods can be found in the online
supplement at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1727/
DC1. All the procedures involving animals and their care were conducted in
accordance with international guidelines, laws, and policies, and with the
National Institutes of Health Principles of Laboratory Animal Care (National
Institutes of Health publication no. 85–23, revised 1985). Most experiments
were conducted with wild-type (WT) and knockout (KO) mice on an SV129
genetic background. Some results were conﬁrmed in C57BL/6 mice. The
protocol was authorized by our local institutions. Diabetes was induced
through a single intraperitoneal injection of 150 mg/kg STZ, and experiments
were performed 4 or 12 weeks after conﬁrmation of hyperglycemia (blood
glucose level 300 mg/dl). Hind limb ischemia was induced by femoral artery
ligation and excision, and experiments were performed 2 weeks later.
Full-thickness skin wounds, 4 mm in diameter, were created on the dorsal
surface of the left hind limbs with a biopsy punch, and closure was monitored
with a digital camera. A block including the wound area with surrounding
tissue was collected for histological analyses at mid-closure time. Tissue
sections were stained with hematoxylin and eosin, Masson trichrome, and
B4-isolectin immunoﬂuorescence. Apoptosis was quantiﬁed with the ApopTag
Plus assay kit. C-myc expression and nuclear localization of -catenin in the
epithelial layer were assessed with quantitative confocal immunoﬂuores-
cence. Skin concentrations of A1C and pentosidine were determined by HPLC,
and -nitrotyrosines were measured with a commercial ELISA kit. Dermal
ﬁbroblasts were isolated from WT and p66Shc
/ mice and cultured in normal
(5 mmol/l) and high (25 mmol/l) glucose in normoxia or hypoxia. Migration
was assessed after growth in monolayer using a commercially available device.
Adductor muscle samples were collected for analysis of necrosis and
inﬂammation (hematoxylin and eosin), apoptosis (ApopTag Plus), and capil-
lary density (B4 isolectin/laminin double immunoﬂuorescence). Perfusion was
assessed in vivo before death with laser doppler perfusion imager. Circulating
endothelial progenitor cells (EPCs) were determined by ﬂow cytometry on the
basis of the expression of CD34 (a stem cell marker) and Flk-1 (type 2
vascular endothelial growth factor receptor) on blood cells. Comparison
between two groups was performed with unpaired Student t test, and
statistical signiﬁcance was accepted at P  0.05.
RESULTS
Diabetes and high glucose induce p66Shc expression
and activation. p66Shc protein expression was deter-
mined in lysates of skin samples from control and diabetic
WT mice. We found that experimental diabetes increased
p66Shc protein content. Serine 36–phosphorylated p66Shc
was increased in diabetic compared with control mice as
well (supplemental Fig. IA), indicating activation of
p66Shc. p66Shc protein expression was also determined in
dermal ﬁbroblasts exposed to normoxia or hypoxia in 5 or
25 mmol/l glucose; we found that high glucose increased
p66Shc expression, especially in the presence of hypoxia
(supplemental Fig. IB). Finally, p66Shc gene expression
was also signiﬁcantly increased in the heart, kidney, and
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FIG. 1. Wound healing. Healing of a 4-mm–diameter cutaneous wound was monitored using digital photography in wild-type (WT) and
p66Shc-knockout (KO) diabetic (DM) and nondiabetic (ND) mice with or without hind limb ischemia. Representative photos are shown. Wound
size is reported as fraction of the initial wound area. On the right, healing time is shown for WT and p66Shc
/ mice with or without diabetes and
limb ischemia on the SV129 or the C57BLC57BL/6 background at 4 or 12 weeks of diabetes duration. n > 3 mice for each group. *P < 0.05 in KO
vs. WT. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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plemental Fig. 1C).
p66Shc knockout accelerates healing of diabetic and
ischemic wounds. Wounds 4 mm in diameter were cre-
ated on the dorsal surface of the right hind limb in WT and
p66Shc
/ SV129 mice, in the presence of either 4-week
STZ-induced diabetes, 2-week hind limb ischemia, or both.
In separated experiments, wounds and ischemia were
induced in WT and p66Shc
/ C57BL/6 mice after 4 and 12
weeks of diabetes and in coeval nondiabetic C57BL/6
mice. Wound area was monitored with a digital camera till
complete macroscopic closure. As shown in Fig. 1, with
both the SV129 and C57BL/6 backgrounds, in nondiabetic
nonischemic animals, wound healing was not different
between WT and p66Shc
/ mice. Four-week diabetes
delayed wound healing by about 70% in WT SV129 animals
and 30% in p66Shc
/ animals, resulting in a signiﬁcantly
faster healing in p66Shc
/ than in WT diabetic nonisch-
emic mice (wound area at day 4: 23.6  2.2 vs. 35.9  5.0%;
P  0.028). Hind limb ischemia delayed wound healing by
about 185% in WT and 70% in p66Shc
/ mice, resulting in
a faster healing in p66Shc
/ versus WT nondiabetic
ischemic mice (P  0.05 from day 1 to 11). The
coexistence of both diabetes and hind limb ischemia
further exacerbated the differences between WT and
p66Shc
/ mice. Similarly, p66Shc deletion in C57BL/6
mice prevented the delay in wound healing induced by
4-week diabetes and hind limb ischemia. In ischemic and
nonischemic C57BL/6 mice 12 weeks after diabetes induc-
tion, absence of p66Shc was associated with signiﬁcantly
faster wound healing compared with the WT micce (Fig. 1,
right panels). With this diabetes duration and genetic
background, induction of ischemia was often followed by
hind limb auto-amputation in WT mice (30 and 50% in
nondiabetic and diabetic animals, respectively), while no
amputation was seen in p66Shc
/ mice (supplementary
Fig. II).
p66Shc knockout rescues the impaired granulation
tissue in diabetic wounds. A well-developed and vascu-
larized granulation tissue is essential for wound healing.
We show that diabetes, especially in combination with
ischemia, impairs development and maturation of the
granulation tissue in WT mice. After 4 weeks of diabetes in
SV129 mice, collagen-stained area (18.7  4.0 vs. 36.0 
2.0%; P  0.002) and thickness of the granulation tissue
(105.5  18.4 vs. 323.0  35.0 m
2; P  0.0001) were
signiﬁcantly reduced in diabetic ischemic wounds com-
pared with control wounds (Fig. 2). Within the granulation
tissue of diabetic wounds, capillary density was reduced
(nonischemic 91.2  12.7 vs. 159.6  11.2 hpf; P  0.002;
ischemic 42.8  6.6 vs. 135.7  18.9 hpf; P  0.002), while
apoptosis was increased (nonischemic 89.9  22.9 vs.
19.2  6.0 hpf; P  0.009) compared with nondiabetic
wounds. In parallel, closure of the epithelial gap was
delayed in diabetic wounds (nonischemic 11.3  3.6 vs.
26.6  4.6%; P  0.015; ischemic 20.6  5.9% vs. 29.4 
6.8%; P  0.33). All these alterations were reversed in
p66Shc
/ mice: collagen area and tissue thickness were
increased in diabetic wounds, while apoptosis was re-
duced and epithelial re-covering was signiﬁcantly im-
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FIG. 2. Characteristics of the granulation tissue in SV129 mice. Several morphological characteristics of the granulation tissue were evaluated
in WT and p66Shc knockout (KO), diabetic (DM) (4-week duration), and nondiabetic (ND) mice with or without hind limb ischemia. Masson
trichrome staining allowed determination of collagen area and granulation tissue thickness. Reepithelialization was quantiﬁed in histological
sections by measuring the percentage of re-covered epithelial gap. Capillary density within the granulation tissue was quantiﬁed by B4 isolectin
immunoﬂuorescence. Apoptosis was assessed with the ApopTag kit in the granulation tissue and at wound edges, a critical site for active wound
healing. Representative images are shown for control (nondiabetic nonischemic) and diabetic ischemic WT and KO mice. n > 3 mice for each
group; n > 5 sections for tissue samples. *P < 0.05 in KO vs. corresponding WT group. †P < 0.05 in diabetic vs. corresponding nondiabetic group.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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granulation tissue was signiﬁcantly lower in nondiabetic
nonischemic p66Shc
/ mice compared withWT mice
(50.8  3.1 vs. 159.6  11.2 hpf; P  0.0001), but this
difference was abrogated in the presence of either diabetes
or ischemia, and was inverted in the presence of both
diabetes and ischemia (92.8  18.7 vs. 42.8  6.6 hpf; P 
0.002). Results were conﬁrmed in mice with the C57BL/6
genetic background after 1 month of diabetes (supplemen-
tary Fig. III). Collectively, these data using two different
mouse strains strongly indicate that deletion of p66Shc
reverts the negative effect of diabetes on development and
ischemia-induced vascularization of the granulation tissue.
p66Shc knockout abrogates nonhealing features of
diabetic wounds. Nonhealing wounds display some typ-
ical cellular and molecular footprints. For example, high
expression of c-myc and nuclear localization of -catenin
have been shown to mark the presence of ulcerogenic
cells at the wound edges, associated with delayed healing
(15). We show in WT mice that diabetic ischemic wounds
had increased expression of c-myc (27.3  7.3 vs. 7.6  3.8
arbitrary units; P  0.03) and nuclear localization of
-catenin (24.1  1.2 vs. 9.4  3.5 arbitrary units; P  0.02)
at their edges compared with control. In p66Shc
/ mice,
development of this nonhealing feature was inhibited, as
diabetic ischemic and nonischemic wounds displayed sig-
niﬁcantly lower expression of c-myc and lower nuclear
-catenin (Fig. 3).
p66Shc knockout reduces nitrotyrosines and pento-
sidine in diabetic skin. Fasting glucose levels were not
signiﬁcantly different between WT and p66Shc
/ diabetic
mice (mean  SEM 388  28 vs. 401  34 mg/dl; P  0.77).
Consistently, glycated hemoglobin was equally increased
in WT and KO diabetic animals compared with nondiabetic
animals (13.8  1.4% vs. 6.6  0.7% and 13.5  1.2% vs.
6.5  0.6%). The skin concentration of nitrotyrosines, a
marker of tissue oxidative stress, was signiﬁcantly in-
creased by 2.5-fold in WT diabetic versus nondiabetic
mice, while it was not signiﬁcantly different in diabetic
versus nondiabetic p66Shc
/ mice. Similarly, skin pento-
sidine concentration, an indicator of advanced glycation,
was signiﬁcantly increased by about 75% in WT diabetic
versus nondiabetic mice, while it was not signiﬁcantly
different in diabetic versus nondiabetic p66Shc
/ mice
(Fig. 4).
Improved migration of dermal ﬁbroblasts in p66Shc
knockout mice. It is well known that deletion of p66Shc
protects from oxidative damage (11). We ﬁrst conﬁrmed
that p66Shc
/ dermal ﬁbroblasts are resistant to hydro-
gen peroxide in vitro, while about 90% WT cells died
(supplemental Fig. IV). We then developed an in vitro
wound model assay using dermal ﬁbroblasts isolated from
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FIG. 3. Biomarkers of epithelial healing. In the epidermis, nuclear localization of -catenin and high expression of c-myc, as features on
nonhealing wounds, were quantiﬁed by immunoﬂuorescence in wild-type (WT) and p66Shc -knockout (KO) diabetic (DM) and nondiabetic (ND)
mice with or without hind limb ischemia. Representative images are shown for control (nondiabetic nonischemic) and diabetic ischemic WT and
KO mice. n > 3 mice for each group; n > 5 sections for tissue samples. *P < 0.05 in KO vs. corresponding WT group. †P < 0.05 in diabetic vs.
corresponding nondiabetic group. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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/ nondiabetic nonischemic mice.
p66Shc
/ cells migrated signiﬁcantly faster than WT
ﬁbroblasts in normoxic 5 mmol/l glucose (% of initial area
at 12 h 5.3  2.2 vs. 22.1  5.9; P  0.037) and when
exposed to high glucose (25 mmol/l) in both normoxia
(12.8  3.2% vs. 36.1  11.0%; P  0.01) and hypoxia
(30.9  4.1% vs. 47.9  2.2%; P  0.026) (Fig. 5). These data
indicate that p66Shc partly mediates the detrimental ef-
fects of hypoxia and high glucose on the migratory activity
of dermal ﬁbroblasts.
Reduced skeletal muscle ischemic damage in p66Shc
knockout mice. Ischemia is a strong inhibitor of wound
healing and a risk factor of wound development, especially
in the setting of diabetes. Thus, we examined the ischemic
responses in WT and p66Shc
/ diabetic and nondiabetic
muscles. In addition to reducing blood ﬂow, ischemia
induced inﬂammation, apoptosis, and necrosis in skeletal
muscle, all of which were worsened by diabetes in WT
animals: compared with nondiabetic WT mice, diabetic
WT mice showed increased apoptotic (48.1  2.2 vs. 2.6 
0.9 hpf; P  0.0001) and necrotic (7.0  1.0 vs. 3.9  0.7
hpf; P  0.002) cell death and inﬂammatory score (385 
72 vs. 210  51 arbitrary units; P  0.023). Postischemic
capillary density and muscle perfusion were lowered by
diabetes in WT mice (capillaries 0.83  0.07 vs. 1.05  0.07
ﬁber; P  0.047; ischemic-to-nonischemic perfusion ratio
0.48  0.06 vs. 0.54  0.05; P  0.05). In p66Shc
/
diabetic mice, necrosis, apoptosis, and inﬂammation did
not increase after ischemia compared with nondiabetic
p66Shc
/ mice. Interestingly, in nondiabetic animals,
p66Shc knockout reduced postischemic perfusion recov-
ery compared with WT animals (capillaries 0.81  0.03 vs.
1.05  0.07 ﬁber; P  0.05; ischemic-to-nonischemic
perfusion ratio 0.30  0.03 vs. 0.54  0.05; P  0.02).
However, p66Shc knockout improved perfusion recovery
in diabetic compared with nondiabetic mice (capillaries
1.15  0.11 vs. 0.81  0.03/ﬁber; P  0.04; ischemic/
nonischemic perfusion ratio 0.40  0.05 vs. 0.30  0.03;
P  0.04), suggesting that p66Shc deletion counteracts the
negative impact of diabetes on blood ﬂow recovery after
ischemia (Fig. 6).
To understand the differential angiogenic response to
ischemia, we assessed circulating endothelial progenitor
cells (EPCs), which normally increase after tissue isch-
emia in control but not in diabetic animals (16,17). In both
diabetic and nondiabetic p66Shc
/ mice, there was no
EPC mobilization after ischemia and baseline levels were
not signiﬁcantly different from WT mice (not shown),
suggesting that the effect of p66Shc on ischemic response
is not mediated by EPCs.
DISCUSSION
We show for the ﬁrst time that deletion of the life
span–determinant redox enzyme p66Shc accelerates heal-
ing of diabetic and ischemic wounds, through induction of
a histologic pattern consistent with reduced tissue dam-
age, enhanced tissue repair, and modulation of the isch-
emic response. Herein, we also conﬁrm our previous
observation that diabetes increases p66Shc gene expres-
sion in humans (10), by showing that diabetes and high
glucose increase p66Shc expression and activation in a
variety of tissues including skin and skeletal muscle.
These data collectively indicate that p66Shc is involved in
the negative effects of diabetes and ischemia on wound
healing.
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2310 DIABETES, VOL. 59, SEPTEMBER 2010 diabetes.diabetesjournals.orgDelayed wound healing represents one of the most
disabling diabetes complications (1–5). It is attributable to
a number of cellular and molecular mechanisms, most of
which are stimulated by oxidative stress (7). p66Shc
generates H2O2, mediates proapoptotic signals, and is
linked to mitochondrial and nonmitochondrial oxidative
stress (9,18). In compliance with the oxidative theory of
aging, deletion of p66Shc prolongs life span by about
30% in mice (19). It is also involved in diseases promi-
nently mediated by oxidative stress, including diabetes
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FIG. 6. Skeletal muscle damage and repair. Several morphological characteristics of skeletal muscle were evaluated in wild-type (WT) and p66Shc
knockout (KO) diabetic (DM) and nondiabetic (ND) mice before and after hind limb ischemia. Hematoxylin and eosin staining was used to
evaluate necrosis and to quantify inﬂammatory inﬁltrate. Apoptosis was quantiﬁed using the ApopTag assay kit while the capillary network was
stained and quantiﬁed using double immunoﬂuorescence for basement membrane (anti–-laminin) and endothelium (anti-GSL I-isolectin B4).
Limb perfusion was monitored 2 weeks after ischemia using a laser-doppler imager. Representative ﬁgures from the different groups of animals
are shown. Histograms report ischemic versus nonischemic rations. n > 3 experiments for each condition; n  5 sections for each tissue sample.
*P < 0.05 in DM vs. ND; †P < 0.05 in KO vs. WT. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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/ mice are protected
against experimental diabetic glomerulopathy (12), diabetic
cardiomyopathy (14), and hyperglycemia-induced endo-
thelial dysfunction (13), indicating that p66Shc is part of
the signal transduction pathway of hyperglycemic damage.
We now present data linking p66Shc to delayed wound
healing. Typical features of nonhealing diabetic wounds
include impaired deposition of the granulation tissue,
which is thinner and devoid of vascular support (21). This
is associated with defective migration of connective tissue
cells within the wound area, delayed apposition of wound
edges, and incomplete reendothelialization (22). In the
present study, we document all these morphological as-
pects of delayed wound healing in a mouse model of
STZ-induced diabetes. Some of these features, such as
defect of granulation tissue and capillary network, were
worsened by the simultaneous presence of diabetes and
limb ischemia. It has been previously shown in chronic
nonhealing lesions that keratinocytes at wound edges have
canonical Wnt-induced -catenin activation; this inhibits
keratinocyte migration by activating c-myc, blocking the
effects of epidermal growth factor, and causing cytoskel-
etal rearrangement (15). We found that the -catenin/
c-myc pathway was overactivated in diabetic ischemic
wounds, consistently with a reduced reendothelialization
and wound closure.
The most important ﬁnding of the present study is that
p66Shc
/ mice showed signiﬁcantly improved healing of
diabetic wounds, in the presence or absence of ischemia.
This was conﬁrmed at 1 and 3 months of diabetes duration
and in both outbred SV129 and inbred C57BL/6 mice. As
shown by nitrotyrosine and pentosidine levels, p66Shc
deletion prevented diabetes-induced oxidative stress and
advanced glycation in the skin. In addition, p66Shc
/
mice had reduced wound edge cell apoptosis and im-
proved migration of connective tissue cells in high glucose
with or without hypoxia. As a result, histologic aspects of
healing were improved in diabetic wounds and ischemic
diabetic wounds of p66Shc
/ mice compared with WT
mice. Furthermore, activation of the -catenin/c-myc path-
way, which prevents epithelial healing, was strongly inhib-
ited by p66Shc deletion in diabetic wounds and ischemic
diabetic wounds. This suggests that oxidative stress and
p66Shc signaling are involved in the deranged epithelial
cell differentiation and migration that mark nonhealing
wounds in diabetes. However, the exact biochemical path-
way that links p66Shc, oxidative stress, and -catenin/
c-myc remains to be deﬁned.
In addition to these local and biochemical events, dia-
betes delays wound healing because it is often compli-
cated by ischemia (23). Diabetic macroangiopathy is
aggressive and often not susceptible to revascularization
(24), resulting in a steady shortage of oxygen and nutrients
to the tissue. Moreover, the local angiogenic response to
ischemia is impaired in diabetes (25). Herein, we conﬁrm
in WT mice that capillary network of diabetic ischemic
wounds is signiﬁcantly reduced compared with nondia-
betic wounds. In hind limb muscles, ischemia caused more
severe damage and inﬂammation in diabetic than in non-
diabetic mice, which was accompanied by a defective
postischemic recovery of vascular network and perfusion.
We found that diabetes induced p66Shc expression in
skeletal muscle, and the excess muscle ischemic damage
associated with diabetes was strongly inhibited by p66Shc
deletion. While capillary density and perfusion were lower
in p66Shc
/ mice at baseline, the postischemic recovery
of skeletal muscle vascularization was signiﬁcantly im-
proved in diabetic versus nondiabetic p66Shc
/ mice.
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diabetic ischemic wounds was doubled by p66Shc dele-
tion, even if SV129 and C57BL/6 mice differed slightly in
the regulation of granulation tissue vascularity. With
longer diabetes duration (12 weeks) on the C57BL/6
background, which is more susceptible to ischemic dam-
age, we also found that p66Shc
/ mice are completely
protected from amputation, which occurred in 30–50% of
WT mice. These data indicate that blocking p66Shc pre-
vents the diabetes-related inhibition of postischemic an-
giogenesis and support a role for p66Shc in regulating
angiogenesis and mediating the negative effects of diabe-
tes on ischemic responses. Despite the fact that p66Shc
has been shown to reverse the defect of diabetic EPCs in
vitro (26), we found no evidence that this is responsible for
the regulation of angiogenesis by p66Shc in vivo, likely
because prevention of the ischemic damage in p66Shc
/
mice reduced the signal for EPC mobilization. The regula-
tion of local angiogenic signals by p66Shc and oxidative
stress deserves further investigation.
Conclusions. In conclusion, we show data supporting
that p66Shc is part of the signaling network that delays
wound healing in diabetes. Genetic deletion of p66Shc
accelerated diabetic wound healing by reducing advanced
glycation, oxidative stress, and tissue damage; promoting
development and vascularization of the granulation tissue;
inhibiting the antihealing -catenin/c-myc epithelial path-
way; and modulating vascular response to ischemia.
p66Shc knockout also signiﬁcantly protected from diabe-
tes-related ischemic damage in limb muscles, a known
factor contributing to diabetic foot disease (Fig. 7). Al-
though the exact biochemical pathways are not yet fully
elucidated, p66Shc is revealed as a potential therapeutic
target against this disabling diabetic complication.
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